EXTREMELY unlikely are my thoughts on this one Kiwiinvestor.....if we are lucky we would maybe get a high level comment like "The Phase three trial is progressing and PAR looks forward to the results...yadda..yadda". Even issuing a statement like this you need to be very careful with your words...WHY?
The reason and proof of this can be found in the following study 1 :
"Maintaining the confidentiality of interim trial data also prevents sponsors, trial investigators, participants, and possible patients from prematurely adopting potentially fallacious trial results; in particular, prior to an expert determination of statistical and clinical significance."
The other proof I can venture is look at what happened during P2 of OA...did we get an update? Nope....
Sure we got two announcements giving us awesome OA results while the P2 was going on back in 2018, but let me assure you this wasn't from the trial itself, it was from the SAS program, quite separate.
My thoughts
REFERENCE
1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813938/#!po=14.5833
Interview with a FDA Process expert..., page-44
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.005(2.04%) |
Mkt cap ! $83.98M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 24.0¢ | $202.2K | 814.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 181098 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 118621 | 5 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |